Nurix-Roche Up to $2.3B Bexobrutideg Deal Closes
Nurix Therapeutics (Nasdaq: NRIX) reported the closing of its previously announced global collaboration with Roche…
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted…
Nurix Q2 revenue $9M; Roche deal up to $2.3B
Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a major global collaboration with Roche for BTK…
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Nurix Therapeutics,…
Nurix, Roche sign $700M BTK degrader deal
0001549595false06/06/20261600 Sierra Point ParkwayBrisbaneCalifornia00015495952026-06-062026-06-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 8-K ___________________________________________ CURRENT REPORT…
Nurix, Roche ink bexobrutideg BTK deal up to $2.3B
Nurix Therapeutics (Nasdaq: NRIX) announced a global collaboration with Roche to co-develop and…
Roche, Nurix in $2.3B BTK degrader alliance
Roche (OTCQX:RHHBY) entered an exclusive global licensing and collaboration agreement with Nurix Therapeutics…